As the application of immune checkpoint inhibitors(ICIs)in the perioperative treatment of melanoma is increasingly introduced at earlier stages,it presents a critical opportunity for the development and clinical translation of neoadjuvant therapy.The results of phaseⅠ/Ⅱ clinical trials on neoadjuvant ICI therapy for melanoma demonstrate that neoadjuvant ICIs effectively improve the pathologic re-sponse rate in melanoma patients.Recent studies have shown that combining ICIs with other treatment modalities,including radiotherapy,chemotherapy,and targeted therapies,can enhance antitumor efficacy of neoadjuvant treatment for patients with melanoma.Optimizing treatment regimens,managing adverse events,identifying and addressing pseudoprogression,and handling cases of oligoprogression have become key areas of research in incorporating ICI regimens into neoadjuvant treatment for patients with melanoma.The search for bio-markers to monitor immunotherapy efficacy is expected to become a major focus of future research.This article provides a review of the re-search progress,controversies,and challenges in the application of ICIs in the neoadjuvant treatment of melanoma,and discusses future re-search directions,aiming to offer insights into the clinical application and development of ICIs in melanoma neoadjuvant therapy.

Immunotherapy has recently shown significant potential in treating malignant tumors.However,the immunosuppressive nature of the tumor microenvironment(TME)limits the number of patients who benefit from this approach.Combining ultrasound with drug-loaded microbubble technology can directly induce tumor cell death through cavitation and pore-forming effects;this promotes tumor anti-gen presentation and enhances immune recognition of these antigens.This strategy also modulates the immunosuppressive state of the tu-mor microenvironment,making it more conducive to an effective immune response.It also normalizes blood vessels and reduces interstitial fluid pressure within the tumor,as well as helps therapeutic agents or genes to penetrate tumor tissues,thereby enhancing overall immune efficacy.This review examines the use of low-intensity ultrasound combined with drug-loaded microbubbles to improve the tumor microen-vironment and boost tumor immune responses.

Colorectal cancer(CRC)is one of the most common malignant tumors worldwide,and its incidence and fatality rates rank at the forefront of malignant tumors.In recent years,with the maturity of laparoscopic and robotic technology,and the application of new staplers,the efficacy and safety of surgery for CRC have improved;however,postoperative complications still seriously affect postoperative quality of life and survival time.Identification of nutritional predictors of CRC is conducive to the early identification of high-risk patients,reinforce-ment of individualized care,enhancement of the quality of peri-operative management,reduction in the incidence of postoperative complic-ations,and improvement of the short-and long-term prognosis.In this paper,the literature on nutritional predictors of postoperative com-plications of CRC was reviewed,the evaluation contents and efficacy of nutritional predictors were summarized,and their advantages and disadvantages were analyzed.The aim is to provide a reference for identifying nutritional predictors of postoperative complications of CRC that are readily accessible,low-cost,and adjustable pre-operatively.

This review summarizes recent advances in neoadjuvant immunotherapy for advanced gastric cancer.Through literature search in PubMed,Web of Science,and CNKI databases from 2020 to 2023,we systematically analyzed the mechanisms,clinical applications,and bio-marker research.Programmed death-1(PD-1)inhibitors combined with chemotherapy significantly improve patient outcomes,while mi-crosatellite instability(MSI),programmed death-ligand 1(PD-L1)expression,and tumor mutational burden(TMB)have been identified as important predictive biomarkers.Multi-omics analysis shows great potential in identifying optimal responders,with pyroptosis-related gene scoring system(PRS)positively correlating with anti-tumor immune infiltration.Metabolic reprogramming and epigenetic regulation in the tumor microenvironment play key roles in immune evasion,while emerging targets such as Claudin 18.2 and combination targeting strategies further enhance therapeutic efficacy.Despite significant progress,precise patient selection and overcoming resistance mechan-isms remain major challenges.Future research should focus on biomarker validation,personalized treatment strategy development,tumor microenvironment dynamic analysis,and novel combination therapy exploration to improve clinical outcomes.

Pseudomyxoma peritonei(PMP)is a rare malignant peritoneal syndrome characterized by progressive intra-abdominal accumu-lation and redistribution of gelatinous tumor-derived mucins.This disease primarily originates in the appendix or ovaries and exhibits distinct biological behavior and clinicopathological features.Carbohydrate antigen 19-9(CA19-9),a critical tumor biomarker,is significantly correl-ated with the development and progression of PMP.This association renders CA19-9 increasingly valuable in clinical diagnosis and treat-ment.Furthermore,molecular biological characteristics of CA19-9,including structural properties,biosynthetic pathways,and mechanisms in mediating tumor metastasis,are systematically elaborated.These findings highlight the association between CA19-9 expression and PMP pathological grading,clinical prognosis,and therapeutic response monitoring.Additionally,the study thoroughly analyzed the synergistic role of CA19-9,alongside other tumor biomarkers,in PMP management.Based on current evidence,future research directions are proposed.These include the potential application of CA19-9 in early PMP diagnosis,its therapeutic utility as a molecular target,and the exploration of CA19-9-associated signaling pathways in PMP pathogenesis.The insights provide novel perspectives and a theoretical foundation for PMP-based precision medicine.

Colorectal cancer,one of the most common malignant tumors worldwide,involves various complex pathophysiological processes.With the in-depth study of molecular science,weidentified lactylation,a new post-translational protein modification,as a key regulator in the initiation and progression of colorectal cancer.Lactylation refers to the modification of lysine residues in proteins by the addition of lactyl groups derived from lactic acid.As a glycolytic end product,lactate accumulates in the tumor microenvironment and regulates gene expres-sion and cellular function by inducing lactylation of histone and non-histone proteins.This article describes how lactylation modification drives tumor immune evasion,metabolic reprogramming,and angiogenesis through epigenetic mechanisms,and elaborates on its impact on the occurrence,metastasis,and multidrug resistance in colon cancer.

Vulvar squamous cell carcinoma(VSCC)is a rare but gradually increasing cancer of the female reproductive system,characterized by a high recurrence rate and poor prognosis.In recent years,significant progress has been made in understanding the etiology,diagnosis,and treatment of VSCC.The classification criteria for VSCC have gradually shifted from histological to molecular levels associated with HPV and P53 protein.More importantly,different molecular subtypes have been proven to exhibit distinct genomic mutations and clinical pro-gnoses.Consequently,the molecular subtypes of VSCC are expected to guide the selection of targeted therapies,immunotherapies,and sur-gical strategies.Simultaneously,the evolution of inguinal lymph node management from traditional surgery to individualized surgical strategies,along with new treatment methods,including electrochemotherapy,targeted therapy,and immunotherapy,has provided more options for the clinical management of VSCC.This review integrates the literature from the past five years to elucidate the latest viewpoints and technologies in the clinical diagnosis and treatment of VSCC,aiming to provide clinicians with a comprehensive perspective to promote a deeper understanding of and management of VSCC.

Objective:To explore the pathogenesis,clinical features,treatment strategies,and prognosis of pediatric lymphoepithelioma-like carcinoma(LELC).Methods:A retrospective analysis was conducted on the clinical data of patients with LELC aged<18 years,treated at Sun Yat-sen University Cancer Center from March 2008 to June 2023.Results:A total of 19 children and adolescents were included in the analys-is,comprising 10 males(52.6%)and 9 females(47.4%),with a median age of 12.9(4.3-17.0)years.Fourteen patients(73.7%)lived in Guangdong province,with the remainder scattered across other regions.Primary LELC sites were the mediastinum(11 cases,57.9%),parot-id glands(4 cases,21%),neck(1 case,5.3%),lungs(1 case,5.3%),salivary glands(1 case,5.3%),and submandibular glands(1 case,5.3%).Among these,15 patients(78.9%)had at least one distant metastasis at initial diagnosis,with common metastasis sites being cervical lymph nodes.Multivariate Cox regression analysis identified tumor volume≥801 cm3 as an independent adverse prognostic factor of poor overall survival(OS)(P<0.01).The 2-year OS and progression-free survival(PFS)rates were 84.2%and 57.9%,respectively.The 2-year OS for pa-tients who underwent surgery,chemotherapy,and radiotherapy was 100%,compared with 25%for those who received only partial treat-ment(P=0.007).The 2-year PFS rate was significantly higher in patients receiving first-line combination therapy with programmed death-1(PD-1)antibodies(100%)compared with those not treated with PD-1 antibodies(38.5%)(P=0.020).For patients with tumor volume≥801 cm3,the 2-year OS was 40.0%,whereas for those with a tumor volume<801 cm3,the 2-year OS was 100%(P<0.001).The 2-year OS for pa-tients who underwent radiotherapy was 100%,while it was 0 for those who did not receive radiotherapy(P<0.001).Conclusions:Pediatric LELC exhibits a relatively favorable prognosis with multidisciplinary treatment,including surgery,chemotherapy,and radiotherapy.The com-bined use of PD-1 antibodies at the time of initial diagnosis could offer potential benefits and warrants further exploration.

Objective:To evaluate the prognostic value of droplet digital PCR(ddPCR)in conjunction with multiparametric flow cytometry(MFC)for measurable residual disease(MRD)detection in predicting relapse risk in patients with acute myeloid leukemia(AML).Methods:In this retrospective cohort study,we have analyzed 78 newly diagnosed patients with AML who underwent combined MRD monitoring using MFC and ddPCR at The Affiliated Hospital of Hebei University(January 2018-January 2025).Clinical outcomes-including MRD negativity rates,cumulative incidence of relapse(CIR),relapse-free survival(RFS),and overall survival(OS)-were systematically evaluated.Prognostic discrim-ination between the MRD-negative and MRD-positive subgroups was compared across standalone and combined detection approaches.Results:With a median follow-up of 17 months(range:2.4-86.7)and a median of one mutation tracked per patient(range:1-3),both MFC-MRD and ddPCR-MRD negative subgroups demonstrated superior 2-year RFS compared with MRD-positive counterparts.Notably,com-bined MFC/ddPCR monitoring enhanced prognostic discrimination,with MRD-negative patients achieving significantly prolonged 2-year RFS compared with MRD-positive patients.MFC-MRD negativity independently predicted improved 2-year OS.Conclusion:ddPCR-based multi-gene MRD profiling provides significant independent prognostic value in patients with AML.The synergistic application of MFC and ddPCR enables superior predictive accuracy for relapse risk and survival outcomes,supporting its integration into standardized MRD monitoring protocols.

Objective:To evaluate the efficacy and safety of treatments in phase Ⅰ oncology clinical trials in patients with advanced non-small-cell lung cancer(NSCLC).Methods:We retrospectively analyzed the clinical data of 65 patients with advanced NSCLC who received phase Ⅰ antitumor trial drugs at the Clinical Trial Research Center of The First Affiliated Hospital of Bengbu Medical University from January 2020 to December 2023.The efficacy and occurrence of serious adverse events(SAEs)were analyzed.Results:The objective response rate(ORR)and disease control rate(DCR)were 9.2%and 61.4%,respectively,whereas the median progression-free survival(PFS)and overall survival(OS)were 2.9 and 15.1 months,respectively.Previously receiving second-line or more lines of treatment and SAE occurrence were independent risk factors for a shorter PFS(P<0.05).A history of smoking and previous second-line or more lines of treatment were inde-pendent risk factors for a shorter OS(P<0.05).The SAE incidence was 15.4%,and no treatment-related deaths occurred.Conclusions:Treat-ments in phase Ⅰ oncology clinical trials are beneficial for patients with advanced NSCLC.Patients with a higher number of previous treat-ment lines and those who experienced SAEs during the trial had a shorter PFS,whereas patients with no smoking history and fewer previous treatment lines had a longer overall survival.The overall safety of the treatments was acceptable.